CRISPR Therapeutics AG Stock Forecast

Stock Price Forecast

According to 25 analysts polled by S&P Global, CRISPR Therapeutics AG stock has a consensus rating of "Buy" and an average price target of $83.52. The average 1-year stock price forecast is 52.08% higher than the current stock price, while the lowest is $44 (-19.88%) and the highest is $291 (+429.86%).

Price Target: $83.52 (+52.08%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$44	$83.52	$76	$291
Change	-19.88%	+52.08%	+38.38%	+429.86%

Analyst Ratings

The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	12	12	12	13	11	11
Buy	5	5	5	4	4	4
Hold	9	9	9	9	9	10
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	1	0
Total	27	27	27	27	25	25

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Maxwell Skor Morgan Stanley	Morgan Stanley	Hold Upgrades $60	Hold	Upgrades	$60	+9.25%	Jun 11, 2026
Unknown Analyst Mizuho Securities No rating	Mizuho Securities	Buy Maintains $85	Buy	Maintains	$85	+54.77%	Jun 10, 2026
Sami Corwin William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 4, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $83	Buy	Maintains	$83	+51.13%	May 14, 2026
William Pickering Bernstein	Bernstein	Hold Reiterates $50 → $56	Hold	Reiterates	$50 → $56	+1.97%	May 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

36.32M

from 3.51M

934.65%

from 3.51M

Revenue Next Year

145.08M

from 36.32M

299.50%

from 36.32M

EPS This Year

-4.82

from -6.47

EPS Next Year

-3.83

from -4.82

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	914.96M	1.20M	371.21M	37.31M	3.51M	36.32M
Revenue Growth	127,154.94%	-99.87%	30,885.48%	-89.95%	-90.59%	934.65%
Gross Profit	473.22M	-570.70M	-146.38M	-393.59M	-494.78M	32.55M
Gross Margin	51.72%	-47,637.48%	-39.43%	-1,054.80%	-14,096.18%	89.63%
Operating Income	373.53M	-673.16M	-222.54M	-466.57M	-568.32M	-532.67M
Net Income	377.66M	-650.18M	-153.61M	-366.25M	-581.60M	-479.11M
EPS	-	-	-	-	-6.47	-4.82
Free Cash Flow	284.82M	-337.58M	-238.97M	-29.27M	-205.62M	-380.36M
No. Analysts	-	-	-	-	-	20

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	251.2M
Avg	36.3M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	7,057.4%
Avg	934.6%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-3.35
Avg	-4.82
Low	-6.37

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-